Keyphrases
Castration-resistant Prostate Cancer
100%
PARP Inhibitor (PARPi)
100%
Treatment Combination
100%
Evolving Landscape
100%
Combination Therapy
28%
Prostate Cancer
28%
Olaparib
28%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
28%
Rucaparib
28%
BRCA mutation
28%
BRCA2 mutation
28%
Phase II Trial
14%
Treatment Choice
14%
Standard of Care
14%
Clinical Development
14%
Disease Course
14%
Talazoparib
14%
Well-defined
14%
FDA-approved Drugs
14%
Androgen Receptor Antagonist
14%
Patient Selection
14%
Early Use
14%
Effective Combination
14%
Expert Opinion
14%
Care Options
14%
Combination Strategy
14%
Homologous Recombination Repair
14%
Area Cover
14%
HRR mutations
14%
Medicine and Dentistry
PARP Inhibitor
100%
Castration Resistant Prostate Cancer
100%
Prostate Cancer
40%
Combination Therapy
40%
Olaparib
40%
Rucaparib
40%
BRCA1
40%
BRCA2
40%
Poly ADP Ribose Polymerase
40%
Androgen Receptor
20%
Homologous Recombination
20%
Disease Course
20%
Patient Selection
20%
Recombination Repair
20%
Talazoparib
20%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Prostate Cancer
40%
Olaparib
40%
Rucaparib
40%
Combination Therapy
40%
Androgen Receptor
20%
Talazoparib
20%
Disease Course
20%